MEOBF — MESOBLAST LTD
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1345099 ·
Last close
$1.89
Market Cap
$2.45B
52W High
$1.89
52W Low
$1.30
ADV30
70
Next earnings
2026-08-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 782,307,000 | 129,573,000 | 207,623,000 |
| Sep 2025 | — | — | — | — | — | — | — |
| Jun 2025 | — | — | — | — | 784,683,000 | 161,158,000 | 187,241,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,051,065,000
Inventory
$21,664,000
Receivables
$43,300,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$65,384,000
EBITDA
$-64,339,000
Free Cash Flow
$-69,438,336
Enterprise Value
$2,131,218,688
Total Cash
$129,975,000
Total Debt
$135,144,000
Shares Out
1,296,960,871
Trailing EPS
$-0.08
Book Value
$0.45
ROE
-18.2%
ROA
-6.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 17,198,000 | -62,443,000 | -102,142,000 | 784,683,000 | 187,241,000 | — | -49,954,000 |
| Jun 2024 | 5,902,000 | -57,972,000 | -87,956,000 | 669,153,000 | 188,798,000 | — | -48,458,000 |
| Jun 2023 | 7,501,000 | -69,289,000 | -81,889,000 | 669,415,000 | 167,577,000 | — | -63,269,000 |
| Jun 2022 | 10,211,000 | -81,107,000 | -91,347,000 | 662,142,000 | 165,098,000 | — | -65,782,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.47B | $9.68 | — |
| KOD | Kodiak Sciences Inc. | $2.34B | $37.22 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.18B | $46.67 | — |
| VCEL | Vericel Corp | $2.17B | $42.30 | — |
| MESO | MESOBLAST LTD | $2.16B | $16.64 | — |
News headlines (Yahoo Finance, 1h cache)
Mesoblast Financial Results and Corporate Update Webcast
2026-08-24 11:00 · Yahoo
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
2026-08-18 15:46 · Yahoo
Sector Update: Healthcare Stocks Mixed Monday Afternoon
2026-08-17 17:38 · Yahoo
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
2026-08-17 14:09 · Yahoo
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
2026-08-17 00:35 · Yahoo
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
2026-07-30 00:57 · Yahoo
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
2026-07-17 16:00 · Yahoo
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
2026-07-14 00:35 · Yahoo
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
2026-07-10 00:30 · Yahoo
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
2026-07-01 00:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.